Vevye now available in US for treatment of dry eye disease
Click Here to Manage Email Alerts
Vevye, a preservative-free, twice-daily 0.1% cyclosporine ophthalmic solution indicated for treatment of signs and symptoms of dry eye disease, is now available in the U.S., according to a manufacturer press release.
“We are excited to see Vevye’s exceptional clinical trial data come to life as U.S. dry eye disease patients are now able to access and experience a highly tolerable product that provides rapid onset of relief and sustained improvement of both signs and symptoms of dry eye disease,” Mark L. Baum, chairman and CEO at Harrow, said in the release.
Approved by the FDA in June 2023, Vevye is dispensed as a 10 µL drop and features the water-free semifluorinated alkane delivery vehicle, perfluorobutylpentane. It has been shown to offer clinical benefits as early as 15 days with sustained improvement over 56 weeks, the company stated, and is being offered to eligible patients with a 100% money-back guarantee.
“When a patient presents with dry eye disease, it is often difficult to initially classify them into a specific category, such as aqueous deficient, evaporative or a combination of the two. In addition, they often present with inflammation leading to many of their dry eye symptoms,” Paul Karpecki, OD, FAAO, director of cornea and external disease at Kentucky Eye Institute, said in the release. “That is why Vevye, with cyclosporine in a semifluorinated alkane solution, provides us with a valuable tool to address the signs and symptoms of dry eye holistically, regardless of etiology.”
Read more about
Click Here to Manage Email Alerts